Fennec Pharmaceuticals

FENC · NASDAQ

$10.46+$0.19 (+1.85%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $10.27

Latest news

Press releaseSep 17, 7:30 AM ETGlobe Newswire
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
NewsAug 11, 7:03 AM ET
Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate
Press releaseAug 11, 7:01 AM ETGlobe Newswire
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseAug 5, 7:01 AM ETGlobe Newswire
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
Press releaseJun 15, 6:00 AM ETGlobe Newswire
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Press releaseMay 21, 6:01 PM ETGlobe Newswire
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
Press releaseMay 18, 4:30 PM ETGlobe Newswire
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsMay 14, 9:32 AM ET
Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
NewsMay 14, 7:11 AM ET
Earnings Scheduled For May 14, 2026
Press releaseMay 14, 6:30 AM ETGlobe Newswire
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Press releaseMay 7, 6:36 AM ETGlobe Newswire
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
Press releaseApr 21, 4:30 PM ETGlobe Newswire
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
NewsApr 7, 7:12 AM ET
Fennec Pharma Initiates Investigator-Sponsored Study By University Of Arizona Cancer Center To Evaluate Use Of PEDMARK In Adolescent And Young Adult And Adult Patients With Head And Neck And Testicular Cancers Receiving Cisplatin
Press releaseApr 7, 7:03 AM ETGlobe Newswire
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
Press releaseMar 31, 6:00 AM ETGlobe Newswire
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsMar 24, 7:11 AM ET
Earnings Scheduled For March 24, 2026
Press releaseMar 24, 7:00 AM ETGlobe Newswire
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
NewsMar 23, 4:40 PM ETAvi Kapoor
Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Press releaseMar 18, 7:08 AM ETGlobe Newswire
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
Press releaseMar 4, 7:05 AM ETGlobe Newswire
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
NewsDec 2, 11:56 AM ETVandana Singh
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power
Press releaseAug 14, 6:08 AM ETGlobe Newswire
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
NewsAug 14, 4:32 AM ET
Earnings Scheduled For August 14, 2025
NewsAug 13, 2:02 PM ET
Fennec Pharmaceuticals Earnings Preview
Press releaseAug 11, 7:12 AM ETGlobe Newswire
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
NewsMay 13, 6:05 AM ET
Fennec Pharmaceuticals Q1 EPS $(0.04) Beats $(0.09) Estimate, Sales $8.75M Beat $8.18M Estimate
Press releaseMay 13, 6:03 AM ETGlobe Newswire
Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
NewsMay 13, 4:32 AM ET
Earnings Scheduled For May 13, 2025
Press releaseMay 8, 4:17 PM ETGlobe Newswire
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
NewsMar 10, 12:59 PM ETErica Kollmann
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?
Press releaseMar 10, 6:03 AM ETGlobe Newswire
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Press releaseMar 6, 4:22 PM ETGlobe Newswire
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
Press releaseFeb 7, 7:00 AM ETGlobe Newswire
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
NewsDec 20, 6:19 AM ET
Fennec's PEDMARQSI Gains National Institute for Health and Care Excellence Support, Offers Hope for Young Patients
Press releaseDec 20, 6:16 AM ETGlobe Newswire
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
Press releaseNov 7, 6:13 AM ETGlobe Newswire
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Press releaseOct 31, 6:23 AM ETGlobe Newswire
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
Press releaseAug 13, 6:05 AM ETGlobe Newswire
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Press releaseAug 6, 4:31 PM ETGlobe Newswire
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026

Fennec Pharmaceuticals Q2 EPS $0.05 Beats $0.02 Estimate, Sales $17.874M Beat $16.095M Estimate

Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript

Earnings Scheduled For May 14, 2026

Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting

Fennec Pharma Initiates Investigator-Sponsored Study By University Of Arizona Cancer Center To Evaluate Use Of PEDMARK In Adolescent And Young Adult And Adult Patients With Head And Neck And Testicular Cancers Receiving Cisplatin

Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings Scheduled For March 24, 2026

Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power

Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update

Earnings Scheduled For August 14, 2025

Fennec Pharmaceuticals Earnings Preview

Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025

Fennec Pharmaceuticals Q1 EPS $(0.04) Beats $(0.09) Estimate, Sales $8.75M Beat $8.18M Estimate

Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Earnings Scheduled For May 13, 2025

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?

Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

Fennec's PEDMARQSI Gains National Institute for Health and Care Excellence Support, Offers Hope for Young Patients

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024